| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 25, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
10-Q - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
EFFECT - Pluri Inc. (0001158780) (Filer)
4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
Pluri launches wholly-owned health and aesthetics subsidiary Cellav- leveraging Pluri's proprietary 3D cell expansion platform to deliver advanced exosome-based technologies for medical aestheticsThe partnership with Miss Universe Skincare, a global beauty and wellness entity, establishes a global distribution channel in the beauty market, which is projected to reach $194.05 billion by 2032 HAIFA, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we", "our" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces the launch of Cell
Pluri entered strategic collaborations across Asia, Europe and the United States ("U.S.") to transform food and agriculture production via its subsidiaries' advanced cell expansion technologies Pluri's subsidiaries Ever After Foods, Kokomodo, and Coffeesai will potentially expand market presence in cultivated meat, cultivated cacao, and cell-based coffee industries amid growing global demand for scalable, sustainable solutionsEach collaboration is anchored by a minimum-viable-product ("MVP"), funded by leading global players entering an agreement. This structure is aimed at bringing the parties' substantial commitment and trust in the collaboration's innovative potential HAIFA, Israel, Nov.
State-backed collaboration outlines a multi-phase, capital-light path from cell line development to pilot-scale biofarming and evaluation of commercial-scale manufacturing in ChiapasCoffeesai leverages Pluri's proprietary 3D cell expansion platform and two decades of expertise to pioneer cell-based coffee solutions resilient to climate change, land constraints, and market volatilityThe global coffee market exceeded $250B in 2024 and is projected to surpass $350B by 2030 (CAGR 5.3% from 2025 to 2030), creating a significant opportunity for scalable, cost-competitive production HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE:
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of
HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company's Board of Directors, effective as of July 11, 2023. Abony is a successful entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He is a globally recognized leader who has invested, directly or indirectly, in more than 20 cellular agriculture and cultivated food companies. Bringing his expertise t
SC 13G/A - Pluri Inc. (0001158780) (Subject)
SC 13G/A - Pluri Inc. (0001158780) (Subject)
SC 13G/A - Pluri Inc. (0001158780) (Subject)
Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ:PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facil